brainQr Therapeutics develops therapies for neurodegenerative diseases by specifically stabilising misfolded proteins.
Its focus is on tau, a key protein in Alzheimer’s disease and more than 30 other diseases. The company was founded by Prof. Dr. Markus Zweckstetter and is based in Göttingen.
Visit website (opens in a new window)